vs
CareDx, Inc.（CDNA）与Repay Holdings Corp（RPAY）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是Repay Holdings Corp的1.5倍（$117.7M vs $78.6M），CareDx, Inc.净利率更高（2.4% vs -178.3%，领先180.7%），CareDx, Inc.同比增速更快（39.0% vs 0.4%），Repay Holdings Corp自由现金流更多（$23.2M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -1.3%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Repay Holdings Corp是一家聚焦北美市场的支付技术服务商，为零售、医疗、汽车服务、电商等领域的企业提供整合支付处理方案，涵盖银行卡收单、ACH转账、POS系统集成等数字化支付工具，助力客户简化交易流程、提升运营效率。
CDNA vs RPAY — 直观对比
营收规模更大
CDNA
是对方的1.5倍
$78.6M
营收增速更快
CDNA
高出38.6%
0.4%
净利率更高
CDNA
高出180.7%
-178.3%
自由现金流更多
RPAY
多$22.7M
$514.0K
两年增速更快
CDNA
近两年复合增速
-1.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $78.6M |
| 净利润 | $2.8M | $-140.1M |
| 毛利率 | — | 74.2% |
| 营业利润率 | 1.0% | -182.2% |
| 净利率 | 2.4% | -178.3% |
| 营收同比 | 39.0% | 0.4% |
| 净利润同比 | — | -3304.1% |
| 每股收益（稀释后） | $0.05 | $-1.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARPAY
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $78.6M | ||
| Q3 25 | $100.1M | $77.7M | ||
| Q2 25 | $86.7M | $75.6M | ||
| Q1 25 | $84.7M | $77.3M | ||
| Q4 24 | $86.6M | $78.3M | ||
| Q3 24 | $82.9M | $79.1M | ||
| Q2 24 | $92.3M | $74.9M |
净利润CDNARPAY
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-140.1M | ||
| Q3 25 | $1.7M | $-6.4M | ||
| Q2 25 | $-8.6M | $-102.3M | ||
| Q1 25 | $-10.4M | $-7.9M | ||
| Q4 24 | $87.7M | $-4.1M | ||
| Q3 24 | $-10.6M | $3.2M | ||
| Q2 24 | $-4.6M | $-4.1M |
毛利率CDNARPAY
| Q1 26 | — | — | ||
| Q4 25 | — | 74.2% | ||
| Q3 25 | — | 74.4% | ||
| Q2 25 | — | 75.7% | ||
| Q1 25 | — | 75.9% | ||
| Q4 24 | — | 76.3% | ||
| Q3 24 | — | 77.8% | ||
| Q2 24 | — | 78.2% |
营业利润率CDNARPAY
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | -182.2% | ||
| Q3 25 | -0.2% | -3.9% | ||
| Q2 25 | -12.8% | -138.7% | ||
| Q1 25 | -15.8% | -4.7% | ||
| Q4 24 | 97.5% | -1.5% | ||
| Q3 24 | -16.6% | -0.9% | ||
| Q2 24 | -7.9% | -4.6% |
净利率CDNARPAY
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -178.3% | ||
| Q3 25 | 1.7% | -8.3% | ||
| Q2 25 | -9.9% | -135.2% | ||
| Q1 25 | -12.2% | -10.3% | ||
| Q4 24 | 101.3% | -5.3% | ||
| Q3 24 | -12.8% | 4.1% | ||
| Q2 24 | -5.0% | -5.4% |
每股收益（稀释后）CDNARPAY
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $-1.68 | ||
| Q3 25 | $0.03 | $-0.08 | ||
| Q2 25 | $-0.16 | $-1.15 | ||
| Q1 25 | $-0.19 | $-0.09 | ||
| Q4 24 | $1.60 | $-0.04 | ||
| Q3 24 | $-0.20 | $0.03 | ||
| Q2 24 | $-0.09 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $115.7M |
| 总债务越低越好 | — | $280.1M |
| 股东权益账面价值 | — | $484.4M |
| 总资产 | $411.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资CDNARPAY
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $115.7M | ||
| Q3 25 | $194.2M | $95.7M | ||
| Q2 25 | $186.3M | $162.6M | ||
| Q1 25 | $230.9M | $165.5M | ||
| Q4 24 | $260.7M | $189.5M | ||
| Q3 24 | $240.9M | $168.7M | ||
| Q2 24 | $228.9M | $147.1M |
总债务CDNARPAY
| Q1 26 | — | — | ||
| Q4 25 | — | $280.1M | ||
| Q3 25 | — | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | — | $496.8M | ||
| Q3 24 | $0 | $496.2M | ||
| Q2 24 | $0 | $435.6M |
股东权益CDNARPAY
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $484.4M | ||
| Q3 25 | $311.1M | $616.9M | ||
| Q2 25 | $327.4M | $633.7M | ||
| Q1 25 | $379.3M | $755.7M | ||
| Q4 24 | $378.4M | $761.3M | ||
| Q3 24 | $273.2M | $754.7M | ||
| Q2 24 | $264.7M | $815.4M |
总资产CDNARPAY
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.2B | ||
| Q3 25 | $432.3M | $1.3B | ||
| Q2 25 | $444.3M | $1.4B | ||
| Q1 25 | $489.6M | $1.5B | ||
| Q4 24 | $491.1M | $1.6B | ||
| Q3 24 | $477.0M | $1.6B | ||
| Q2 24 | $466.8M | $1.5B |
负债/权益比CDNARPAY
| Q1 26 | — | — | ||
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | 0.00× | 0.66× | ||
| Q2 24 | 0.00× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $23.2M |
| 自由现金流率自由现金流/营收 | 0.4% | 29.6% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $90.7M |
8季度趋势，按日历期对齐
经营现金流CDNARPAY
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $23.3M | ||
| Q3 25 | $37.4M | $32.2M | ||
| Q2 25 | $9.9M | $33.1M | ||
| Q1 25 | $-26.6M | $2.5M | ||
| Q4 24 | $21.9M | $34.3M | ||
| Q3 24 | $12.5M | $60.1M | ||
| Q2 24 | $18.9M | $31.0M |
自由现金流CDNARPAY
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $23.2M | ||
| Q3 25 | — | $32.1M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $34.0M | ||
| Q3 24 | — | $59.8M | ||
| Q2 24 | — | $30.5M |
自由现金流率CDNARPAY
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 29.6% | ||
| Q3 25 | — | 41.3% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 43.5% | ||
| Q3 24 | — | 75.6% | ||
| Q2 24 | — | 40.7% |
资本支出强度CDNARPAY
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% |
现金转化率CDNARPAY
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | 18.52× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
